SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
  • 2
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
  • 3
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
  • 4
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
  • 5
    Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011; 43: 259-265.
  • 6
    Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. HEPATOLOGY 1989; 10: 198-202.
  • 7
    Hadziyannis S, Bramon T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment for HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol 1990; 11( Suppl. l): S133-S136.
  • 8
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-313.
  • 9
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270.
  • 10
    Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, et al. Long-term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94: 1366-1372.
  • 11
    Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109.
  • 12
    Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. HEPATOLOGY 1997; 26: 1621-1625.
  • 13
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
  • 14
    Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. HEPATOLOGY 2003; 37: 756-763.
  • 15
    Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.
  • 16
    Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine, and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
  • 17
    Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, et al. Hepatitis C pharmacogenetics: state of the art in 2010. HEPATOLOGY 2011; 53: 336-345.
  • 18
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 46: 399-401.
  • 19
    Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
  • 20
    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
  • 21
    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
  • 22
    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
  • 23
    McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
  • 24
    Ishak K, Baptista A, Bianchi L, Suchindran S, Lao XQ, Patel K, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
  • 25
    Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14: 1183-1188.
  • 26
    Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. HEPATOLOGY 2010; 52: 454-461.
  • 27
    Rijckborst V, Hansen BE, Ferenci F, Brunetto MR, Tabak F, Cakaloglu Y, et al. Early on-treatment HBsAg and HBV DNA levels identify HBeAg-negative patients not responding to 48 or 96 weeks of peginterferon alfa-2a therapy. HEPATOLOGY 2010; 52( Suppl 4): 479A.
  • 28
    Sonneveld MJ, Wong VW, Wotman AM, Wong GLH, Buster EHCJ, Hansen BE, et al. Polymorphisms at rs12979860 and rs12980275 near IL28B predict serological response to (Peg)-interferon in HBeAg-positive chronic hepatitis B. J Hepatol 2011; 54 ( Suppl 1): S32.
  • 29
    Sarasin-Filipowicz M, Oakeley EJ, Duong F, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. PNAS 2008; 105: 7034-7039.
  • 30
    Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, et al. IL28B polymorphism predicts virologic response in atients with hepatitis C genotype 1 treated with boceprevir (Boc) combination therapy. J Hepatol 2011; 54( Suppl 1): S6.
  • 31
    Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. J Hepatol 2011; 54( Suppl 1): S542-S543.